AbClon Inc
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more
AbClon Inc - Asset Resilience Ratio
AbClon Inc (174900) has an Asset Resilience Ratio of 14.74% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how AbClon Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down AbClon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.86 Billion | 5.64% |
| Short-term Investments | ₩3.00 Billion | 9.1% |
| Total Liquid Assets | ₩4.86 Billion | 14.74% |
Asset Resilience Insights
- Moderate Liquidity: AbClon Inc has 14.74% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
AbClon Inc Industry Peers by Asset Resilience Ratio
Compare AbClon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for AbClon Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for AbClon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 45.37% | ₩21.86 Billion | ₩48.18 Billion | +6.85pp |
| 2023-12-31 | 38.53% | ₩17.50 Billion | ₩45.42 Billion | -6.13pp |
| 2022-12-31 | 44.65% | ₩24.14 Billion | ₩54.06 Billion | +10.24pp |
| 2021-12-31 | 34.42% | ₩10.27 Billion | ₩29.83 Billion | -14.30pp |
| 2020-12-31 | 48.72% | ₩19.55 Billion | ₩40.13 Billion | -11.83pp |
| 2019-12-31 | 60.55% | ₩28.44 Billion | ₩46.97 Billion | -11.02pp |
| 2018-12-31 | 71.57% | ₩20.54 Billion | ₩28.70 Billion | -10.40pp |
| 2017-12-31 | 81.97% | ₩17.10 Billion | ₩20.87 Billion | +9.25pp |
| 2016-12-31 | 72.72% | ₩11.64 Billion | ₩16.01 Billion | +10.87pp |
| 2015-12-31 | 61.85% | ₩10.00 Billion | ₩16.17 Billion | -- |